Search
Research
The Spectrum, Severity and Outcomes of Rheumatic Mitral Valve Disease in Pregnant Women in Australia and New ZealandRheumatic heart disease (RHD) poses significant perinatal risks. We aimed to describe the spectrum, severity and outcomes of rheumatic mitral valve disease in pregnancy in Australia and New Zealand.
Research
Roadmap to incorporating group A Streptococcus molecular point-of-care testing for remote Australia: a key activity to eliminate rheumatic heart diseaseJonathan Asha Dylan Rosemary Janessa Jeffrey Carapetis AM Bowen Barth Wyber Pickering Cannon AM MBBS FRACP FAFPHM PhD FAHMS BA MBBS DCH FRACP PhD
Research
Outcomes of latent rheumatic heart disease: External validation of a simplified score in patients with and without secondary prophylaxisSecondary antibiotic prophylaxis reduces progression of latent rheumatic heart disease (RHD) but not all children benefit. Improved risk stratification could refine recommendations following positive screening. We aimed to evaluate the performance of a previously developed echocardiographic risk score to predict mid-term outcomes among children with latent RHD.
Research
Low positive predictive value of International Classification of Diseases, 10th Revision codes in relation to rheumatic heart disease: a challenge for global surveillanceWe outline a series of research initiatives to improve identification of RHD in administrative data thereby contributing to monitoring the RHD burden globally
Research
Contemporary Incidence and Prevalence of Rheumatic Fever and Rheumatic Heart Disease in Australia Using Linked Data: The Case for Policy ChangeJonathan Judy Alex Jeffrey Rosemary Carapetis AM Katzenellenbogen Brown Cannon Wyber AM MBBS FRACP FAFPHM PhD FAHMS BSc (Occ Ther) BSc Hons (
Research
Development of a sustained release implant of benzathine penicillin G for secondary prophylaxis of rheumatic heart diseaseRegular intramuscular (i.m.) benzathine penicillin G (BPG) injections have been the cornerstone of rheumatic heart disease (RHD) secondary prophylaxis since the 1950s. Patient adherence to IM BPG is poor, largely due to pain, the need for regular injections every 3-4 weeks and health sector delivery challenges in resource-limited settings. There is an urgent need for new approaches for secondary prophylaxis, such as an implant which could provide sustained penicillin concentrations for more than 6 months.
Research
The evidence that rheumatic heart disease control programs in Australia are making an impactRheumatic heart disease (RHD) comprises heart-valve damage caused by acute rheumatic fever (ARF). The Australian Government Rheumatic Fever Strategy funds RHD Control Programs to support detection and management of ARF and RHD. We assessed epidemiological changes during the years of RHD Control Program operation.
Research
Myositis complicating benzathine penicillin-G injection in a case of rheumatic heart diseaseA 7-year old boy developed myositis secondary to intramuscular injection of benzathine penicillin-G in the context of secondary prophylaxis for RF
Research
Rheumatic Heart Disease Severity, Progression and Outcomes: A Multi‐State ModelThe prognosis of young Indigenous Australians diagnosed with severe RHD is bleak; interventions must focus on earlier detection and treatment
Research
Acute rheumatic fever and rheumatic heart diseaseAcute rheumatic fever (ARF) is the result of an autoimmune response to pharyngitis caused by infection with group A Streptococcus.